Search

Your search keyword '"Human T-lymphotropic virus 1 enzymology"' showing total 66 results

Search Constraints

Start Over You searched for: Descriptor "Human T-lymphotropic virus 1 enzymology" Remove constraint Descriptor: "Human T-lymphotropic virus 1 enzymology"
66 results on '"Human T-lymphotropic virus 1 enzymology"'

Search Results

1. The Effects of Side-Chain Configurations of a Retro-Inverso-Type Inhibitor on the Human T-Cell Leukemia Virus (HTLV)-1 Protease.

2. Cryo-EM structure of the deltaretroviral intasome in complex with the PP2A regulatory subunit B56γ.

3. Structural basis of host protein hijacking in human T-cell leukemia virus integration.

4. B'-protein phosphatase 2A is a functional binding partner of delta-retroviral integrase.

5. Privileged Structures Meet Human T-Cell Leukemia Virus-1 (HTLV-1): C2-Symmetric 3,4-Disubstituted Pyrrolidines as Nonpeptidic HTLV-1 Protease Inhibitors.

6. Characterizing the protonation states of the catalytic residues in apo and substrate-bound human T-cell leukemia virus type 1 protease.

7. Molecular insights of protein contour recognition with ligand pharmacophoric sites through combinatorial library design and MD simulation in validating HTLV-1 PR inhibitors.

8. Molecular insights on analogs of HIV PR inhibitors toward HTLV-1 PR through QM/MM interactions and molecular dynamics studies: comparative structure analysis of wild and mutant HTLV-1 PR.

9. Effect of prime-site sequence of retro-inverso-modified HTLV-1 protease inhibitor.

10. A comparative study of HIV-1 and HTLV-I protease structure and dynamics reveals a conserved residue interaction network.

11. Development of [Ile⁴⁰]HTLV-I protease inhibition assay using novel fluorogenic and chromogenic substrate.

12. Design and synthesis of several small-size HTLV-I protease inhibitors with different hydrophilicity profiles.

13. Maintaining potent HTLV-I protease inhibition without the P3-cap moiety in small tetrapeptidic inhibitors.

14. Crystal structures of inhibitor complexes of human T-cell leukemia virus (HTLV-1) protease.

15. Total chemical synthesis of human T-cell leukemia virus type 1 protease via native chemical ligation.

16. C-terminal residues of mature human T-lymphotropic virus type 1 protease are critical for dimerization and catalytic activity.

17. The HTLV-1 Tax interactome.

18. Locking the two ends of tetrapeptidic HTLV-I protease inhibitors inside the enzyme.

19. Truncation and non-natural amino acid substitution studies on HTLV-I protease hexapeptidic inhibitors.

20. Effect of phosphonated carbocyclic 2'-oxa-3'-aza-nucleoside on human T-cell leukemia virus type 1 infection in vitro.

21. Phosphonated carbocyclic 2'-oxa-3'-azanucleosides as new antiretroviral agents.

22. Bovine leukemia virus protease: comparison with human T-lymphotropic virus and human immunodeficiency virus proteases.

23. Phenotypic and genotypic comparisons of human T-cell leukemia virus type 1 reverse transcriptases from infected T-cell lines and patient samples.

24. Activation of NF-kappa B by the human T cell leukemia virus type I Tax oncoprotein is associated with ubiquitin-dependent relocalization of I kappa B kinase.

25. The protease of human T-cell leukemia virus type-1 is a potential therapeutic target.

26. Synthesis, processing, and composition of the virion-associated HTLV-1 reverse transcriptase.

27. Crystal structure of human T cell leukemia virus protease, a novel target for anticancer drug design.

28. Amino acid preferences for a critical substrate binding subsite of retroviral proteases in type 1 cleavage sites.

29. Design of inhibitors against HIV, HTLV-I, and Plasmodium falciparum aspartic proteases.

30. The 10 C-terminal residues of HTLV-I protease are not necessary for enzymatic activity.

31. Narrow substrate specificity and sensitivity toward ligand-binding site mutations of human T-cell Leukemia virus type 1 protease.

32. Understanding HTLV-I protease.

33. Lamivudine resistance in human T-cell leukemia virus type 1 may be due to a polymorphism at codon 118 (V-->I) of the reverse transcriptase.

34. Identification of the RT-RH/IN cleavage site of HTLV-I.

35. N-Terminal domain of HTLV-I integrase. Complexation and conformational studies of the zinc finger.

36. Susceptibility of human T cell leukemia virus type 1 to reverse-transcriptase inhibitors: evidence for resistance to lamivudine.

37. Proteolytic processing of the human T-cell lymphotropic virus 1 reverse transcriptase: identification of the N-terminal cleavage site by mass spectrometry.

38. Identification of poly(ADP-ribose) polymerase as a transcriptional coactivator of the human T-cell leukemia virus type 1 Tax protein.

39. Effect of lamivudine on human T-cell leukemia virus type 1 (HTLV-1) DNA copy number, T-cell phenotype, and anti-tax cytotoxic T-cell frequency in patients with HTLV-1-associated myelopathy.

40. Stabilization from autoproteolysis and kinetic characterization of the human T-cell leukemia virus type 1 proteinase.

41. Characterization of human T-cell leukemia virus type I integrase expressed in Escherichia coli.

42. Substrates and inhibitors of human T-cell leukemia virus type I protease.

43. Isolation of a retrovirus from multiple sclerosis patients in self-generated Iodixanol gradients.

44. Human T-cell leukemia virus type 1 reverse transcriptase (RT) originates from the pro and pol open reading frames and requires the presence of RT-RNase H (RH) and RT-RH-integrase proteins for its activity.

45. Efficient expression and rapid purification of human T-cell leukemia virus type 1 protease.

46. Zidovudine treatment is not associated with HTLV-1 reverse transcriptase gene mutations in HTLV-I/HIV-1 co-infected patients.

47. Substrates and inhibitors of human T-cell leukemia virus type 1 (HTLV-1) proteinase.

48. Retrovirus in salivary glands from patients with Sjögren's syndrome.

49. Mouse monoclonal antibodies directed against the HTLV-I protease recognize epitopes internal to the dimer.

50. Analysis of cross reactivity of retrovirus proteases using a vaccinia virus-T7 RNA polymerase-based expression system.

Catalog

Books, media, physical & digital resources